Results 1 to 10 of about 1,690 (150)

Epigenetic Silencing of RFX7 Defines a Transcriptional Axis Linking Lactate Metabolism to Immune Checkpoint Therapy in Glioblastoma [PDF]

Advanced Science
Glioblastoma (GBM) is a highly aggressive brain tumor characterized by rapid proliferation, diffuse invasion, and robust immunosuppression. Although excessive aerobic glycolysis and lactate accumulation are known to contribute to an immunosuppressive ...
Liying Han, Jinpeng Zhou, Gang Zhu, Fan Chen, Leiyang Li, Wenxing Cui, Fang Sun, Tian Feng, Yue Zhang, Qiang Wang, Shuoyao Ma, Chengxuan Guo, Ziwen Zhang, Kai Wang, Jiahui Wang, Liangbo Wang, Wencong Li, Chenyi Yuan, Haixiao Liu, Liang Wang, Yan Qu   +20 more
doaj   +3 more sources

Efficacy of stiripentol, fenfluramine, and their combination on clinical outcomes in Dravet syndrome: A preliminary report. [PDF]

Epilepsia Open
Abstract Objective Stiripentol and fenfluramine are approved treatments for Dravet syndrome (DS), but real‐world data comparing their effectiveness and combined use remain limited. Our study aims to explore associations between treatment with stiripentol, fenfluramine, and their combination and clinical outcomes in patients with DS.
Surdi P, Trivisano M, Mercier M, Pietrafusa N, De Dominicis A, Calabrese C, Cappelletti S, Specchio N.   +7 more
europepmc   +2 more sources

Stiripentol use in Dravet syndrome patients in the USA: Results of a real‐world study [PDF]

Epilepsia Open
Objective Dravet syndrome (DS) is a severe developmental and epileptic encephalopathy with a high seizure burden and mortality risk. Stiripentol, one of the first DS‐specific therapies, received FDA approval in 2018 but its real‐world use and impact post‐
Elaine Wirrell, James Wheless, Michael Scott Perry, Linda Laux, Karen C. Keough, Julie Ziobro, Aimee F. Luat, Gewalin Aungaroon, Michael A. Ciliberto, Roxane Noel, Laurent Chancharme, Joseph Sullivan   +11 more
doaj   +2 more sources

Efficacy and safety of fenfluramine in Dravet syndrome: The impact of patient clinical characteristics. [PDF]

Epilepsia Open
This graphical abstract provides an overview of the content from this post hoc analysis evaluating the efficacy and safety of fenfluramine in patients with Dravet syndrome stratified by age, number of previously attempted antiseizure medications, and SCN1A pathogenic variant status using data pooled from the three pivotal randomized controlled trials ...
Nabbout R, Sullivan J, Auvin S, Cross JH, Devinsky O, Gil-Nagel A, Guerrini R, Knupp KG, Perry MS, Sánchez-Carpintero R, Schoonjans AS, Scheffer IE, Specchio N, Strzelczyk A, Wheless J, Wirrell EC, Morita D, Healy P, Langlois M, Lothe A, Lagae L.   +20 more
europepmc   +2 more sources

Safety of Drugs Used in Difficult-to-Treat Epileptic Syndromes: A Disproportionality Analysis Using the Eudravigilance Database [PDF]

Pharmaceuticals
Background/Objectives: Difficult-to-treat epileptic syndromes include conditions typically emerging in the first years of life and are characterized by a high rate of drug refractoriness. This study aimed to better define the safety profile of drugs used
Arianna Scala, Teresa Angela Trunfio, Chiara Pennisi, Giovanni Enrico Lombardo, Vincenzo Micale, Serena Di Martino, Giorgia Fiorenza, Adriana Carol Eleonora Graziano, Marilena Briglia, Fabio Allia, Giovanni Giurdanella, Roberta Malaguarnera, Rosalia Battaglia, Cecilia Gozzo, Fanny Erika Palumbo, Calogero Vetro, Giovanni Improta, Mario Damiano Toro, Filippo Drago, Giovanni Luca Romano, Lucia Gozzo   +20 more
doaj   +2 more sources

Efficacy of Stiripentol Beyond Dravet Syndrome: A Retrospective Medical Record Review of Patients with Drug-Resistant Epilepsies [PDF]

Neurology and Therapy
Introduction Stiripentol is approved as an add-on therapy with clobazam and/or valproate for seizures associated with Dravet syndrome (DS). Evidence of stiripentol efficacy in other drug-resistant epilepsies is limited.
Víctor Soto-Insuga, Elena González-Alguacil, María Ballarà-Petitbò, Nuria Lamagrande-Casanova, Anna Duat-Rodríguez, Cristina Benítez-Provedo, Elena Cardenal-Muñoz, Juan José García-Peñas   +7 more
doaj   +2 more sources

Employing zebrafish to understand genetic drivers of epilepsy-related comorbid behaviors [PDF]

Frontiers in Pharmacology
Children with epilepsy frequently experience a range of significant comorbidities beyond seizures, such as motor dysfunction, cognitive impairment, and neurodevelopmental delays. In some cases, these comorbidities contribute more significantly to overall
Chinwendu Ononuju, Kharma Hall, Olivia Beatty, Scott C. Baraban, Colleen Carpenter-Swanson, Colleen Carpenter-Swanson   +5 more
doaj   +2 more sources

From first seizure to specific antiseizure medication in Dravet syndrome: Quantifying delays in the DS'coverED study. [PDF]

Epilepsia Open
Abstract Objective Dravet syndrome (DS) is a rare early‐onset developmental and epileptic encephalopathy with persistent delays between seizure onset and diagnosis. The DS'coverED study aimed to characterize current diagnostic timelines by examining each step and its duration, identifying residual barriers, and actionable solutions to optimize the ...
Christodoulou L, Ballarà Petitbò M, Aguilera Albesa S, Borroni S, Hugon P, Kumar R, Messana T, Meyer P, Villéga F, Klotz KA.   +9 more
europepmc   +2 more sources

Practical consensus recommendations for polytherapy involving stiripentol in Dravet syndrome: A nominal group approach [PDF]

Epilepsia Open
Objectives Dravet syndrome (DS) is a drug‐resistant developmental and epileptic encephalopathy, often requiring three or more antiseizure medications (ASMs).
J. Helen Cross, Rima Nabbout, Barry Gidal, Joseph Sullivan, Elaine Wirrell   +4 more
doaj   +2 more sources

Hypoxia-Induced Histone Lactylation Drives Cisplatin Resistance in Bladder Cancer by Promoting RBM15-Dependent m6A Methylation of IGFBP3 [PDF]

Research
Histone lactylation modification and RNA m6A modification play important roles in cisplatin resistance of bladder cancer (BCa). Hypoxia drives cisplatin resistance in BCa by analyzing the TCGA-BLCA cohort, where hypoxia signatures predicted poor overall ...
Jiazhu Sun, Yuchen Shi, Kai Yu, Suyuelin Huang, Dingheng Lu, Xinyang Niu, Yuxiao Li, Feifan Wang, Xueyou Ma, Jiangfeng Li, Xiaoyan Liu, Liping Xie, Haojie Huang, Ben Liu   +13 more
doaj   +2 more sources